{"entity":{"id":"andrea-decensi","kind":"person","name":"Andrea DeCensi","aka":[],"tldr":"Italian oncologist who led TAM-01, the trial that showed a low dose of tamoxifen halves recurrence after non-invasive breast cancer with fewer side effects than the standard dose.","summary":"Andrea DeCensi is a medical oncologist at Galliera Hospital in Genoa who has spent his career on breast cancer prevention. He was first author of the 2019 Journal of Clinical Oncology report of TAM-01, an Italian trial in which tamoxifen at 5 mg a day for three years reduced recurrence and new breast cancers after ductal carcinoma in situ and other non-invasive lesions, with a toxicity profile little different from placebo. Low-dose tamoxifen is now an option in guidelines for risk reduction.","asOf":"2026-09-18","links":[],"tags":["breast","prevention","trialist"],"related":[],"cancers":["ductal-carcinoma-in-situ","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ospedali-galliera"],"pathways":[],"terms":[],"trials":["tam-01"],"people":[],"bottlenecks":[],"keyPapers":["paper-andrea-decensi-cancer-prev-res-phila-2014","paper-andrea-decensi-diabetologia-2017","paper-andrea-decensi-j-clin-oncol-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, E.O. Ospedali Galliera, Genoa","institutionId":"ospedali-galliera","specialisms":["Breast cancer prevention","Low-dose tamoxifen","Chemoprevention trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=DeCensi%5BAuthor%5D"}],"papers":[{"title":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","journal":"Cancer prevention research","year":2014,"url":"https://doi.org/10.1158/1940-6207.capr-13-0424","doi":"10.1158/1940-6207.capr-13-0424","note":"Europe PMC author record matched by affiliation (E.O. Ospedali Galliera); 325 citations on Europe PMC."},{"title":"Repurposing metformin for the prevention of cancer and cancer recurrence","journal":"Diabetologia","year":2017,"url":"https://doi.org/10.1007/s00125-017-4372-6","doi":"10.1007/s00125-017-4372-6","note":"Europe PMC author record matched by affiliation (E.O. Ospedali Galliera); 232 citations on Europe PMC."},{"title":"Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update","journal":"Journal of Clinical Oncology","year":2019,"url":"https://doi.org/10.1200/jco.19.01472","doi":"10.1200/jco.19.01472","note":"Europe PMC author record matched by affiliation (E.O. Ospedali Galliera); 169 citations on Europe PMC."}]},"route":"/people/andrea-decensi/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/"}],"institution":[{"id":"ospedali-galliera","kind":"institution","name":"E.O. Ospedali Galliera","route":"/institutions/ospedali-galliera/"}],"trial":[{"id":"tam-01","kind":"trial","name":"TAM-01","route":"/trials/tam-01/"}],"paper":[{"id":"paper-andrea-decensi-cancer-prev-res-phila-2014","kind":"paper","name":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","route":"/key-papers/paper-andrea-decensi-cancer-prev-res-phila-2014/"},{"id":"paper-andrea-decensi-diabetologia-2017","kind":"paper","name":"Repurposing metformin for the prevention of cancer and cancer recurrence","route":"/key-papers/paper-andrea-decensi-diabetologia-2017/"},{"id":"paper-andrea-decensi-j-clin-oncol-2019","kind":"paper","name":"Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update","route":"/key-papers/paper-andrea-decensi-j-clin-oncol-2019/"}]}}